Effects of Wei Chang An pill(胃肠安丸) on enzyme activity and levels of vasoactive peptide and substance P in the small intestine of rats with compound diarrhea

OBJECTIVE:To investigate the regulatory effects of Wei Chang An Pill(WCAP) on enzyme activity and gastrointestinal hormones in the small intestine of rats with compound diarrhea.METHODS:Forty Wistar rats were randomly divided into a control,diarrhea model,and WCAP high,medium,and low dose groups.The control group was not treated,and the model group was administered intragastric distilled water.The WCAP groups were given WCAP suspension,80,60 or 40 mg · kg-1 · d-1,for 4 days.Stool properties were observed.After the experiment,thymus and spleen indices were measured,and the activities of lactate dehydrogenase(LDH),malate dehydrogenase(MDH),and disaccharidase(lactase) in the small intestinal mucous membrane,and levels of substance P(SP) and vasoactive peptide(VIP) in the colon were determined.RESULTS:Compared with the control group,thymus and spleen indices were significantly decreased,LDH,MDH,and disaccharidase activity in the small intestine was decreased,and SP and VIP levels in the colon were significantly increased inthe diarrhea model group.Compared with the model group,thymus and spleen indices were significantly increased,and LDH,MDH,and disaccharidase activity in the small intestine and SP and VIP levels in the colon were significantly decreased in theWCAP medium dose group.CONCLUSION:The diarrhea model rats exhibited pathological changes including atrophy of the thymus and spleen,decreased enzyme activity in the small intestine,and gastrointestinal hormone disturbance.WCAP can increase the activity of intestinal digestive enzymes and regulate gastrointestinal hormones,thereby relieving diarrhea.

胃肠安丸对溃疡性结肠炎模型小鼠Treg/Th17免疫平衡的影响

目的探讨胃肠安丸治疗溃疡性结肠炎的可能作用机制。方法60只C57BL/6小鼠随机选取10只为正常组,其余小鼠给予2.5%葡聚糖硫酸钠(DSS)水溶液自由饮用7天复制UC小鼠模型,将造模成功的50只小鼠再随机分为模型组、美沙拉嗪组和胃肠安丸高、中、低剂量组,每组10只。胃肠安丸低、中、高剂量组分别给予胃肠安丸混悬液0.015、0.03、0.06g/(kg·d)灌胃,美沙拉嗪组给予美沙拉嗪混悬液0.52g/(kg·d)灌胃,正常组和模型组给予0.5ml纯净水灌胃,每日1次,连续10天。每天观察各组小鼠体质量、大便性状及便血情况,并计算疾病活动指数(DAI)。药物干预结束后处死小鼠,测量结肠长度,对结肠组织进行HE染色,观察远端结肠组织病理形态学变化,流式细胞术检测小鼠脾脏调节性T细胞(Treg)、辅助性T细胞17(Th17)百分比及比值。结果干预后与模型组和胃肠安丸低剂量组比较,美沙拉嗪组、胃肠安丸高剂量组小鼠体重差值增加,DAI评分差值升高(P<0.05)。与正常组比较,模型组小鼠结肠长度减少,病理学评分升高,Treg细胞百分比、Treg/Th17值降低,Th17细胞百分比升高(P<0.05);与模型组比较,美沙拉嗪组、胃肠安丸高剂量组小鼠结肠长度增长,病理学评分降低,Treg细胞百分比、Treg/Th17值升高,Th17细胞百分比降低(P<0.05)。美沙拉嗪组、胃肠安丸高剂量组各指标组间比较差异无统计学意义(P>0.05)。结论胃肠安丸在改善DSS诱导的溃疡性结肠炎小鼠腹泻、便血、体质量下降等症状和修复肠道黏膜损伤方面与美沙拉嗪功效相近,其作用机制可能与调节Treg/Th17免疫失衡有关。